title: In-Vitro and in-Silico characterization of Sophora interrupta plant extract as an anticancer activity.
abstract: Sophora interrupta belongs to the family of Fabaceae and the species in this genus have a diverse medicinal importance as a folk medicine for preventing many ailments including cancer. In order to evaluate the anticancer activity of S.interrupta, we have performed in vitro anti-oxidant, anti-inflammatory, anti-proliferative, and cell based anticancer activity in MCF-7 and PC-3 cell lines. Secondary metabolites of S.interrupta were used to identify anticancer compounds using Open Eye software. The antioxidant activity of the S.interrupta root ethylacetate (SEA) extract at 100 µg/ml is equal to that of ascorbic acid at 50 µg/ml. The antiinflammatory activity of SEA is half of that of diclofenac at 50 µg/ml. Anticancer activity was detected by measuring the mitochondrial dehydrogenase activity (MTT assay). The half maximal inhibitory concentrations (IC50) for MCF-7 and PC-3 cell lines are 250 and 700 µg/ml respectively. This was supported by the morphological changes such as membrane blebbing, cell detachment and rounded cell morphology when compared to the parental cells. In addition, we observed few green cells (live) over red cells (dead) based on the uptake of acridine orange and ethidium bromide dyes. Kaempferol-3-O-b-D-glucopyranoside, a Secondary metabolite of S.interrupta form 6 hydrogen bond interactions with Arg 202, Gln 207, Gly 227, Gly 229, Thr 231 and Ala 232 human DEAD box RNA helicase, DDX3 protein and is equivalent to crystal structure of adenosine mono phosphate to DDX3. Overall, it suggests that the SEA extract has anticancer compounds, and it can be used to enhance death receptor mediated cancer cell death.
authors.affiliation: Biomedical research Laboratory, Department of Biotechnology, K L University, Green fields, Vaddeswaram, Guntur 522 502, AndhraPradesh, India.
authors.forename: Pardhasaradhi
authors.initials: P
authors.lastname: Mathi
authors.affiliation: Molecular Endocrinology Laboratory, Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247 667, Uttarakhand, India.
authors.forename: Kumar
authors.initials: K
authors.lastname: Nikhil
authors.affiliation: Department of Biochemistry, Acharya Nagarjuna University, Guntur, India.
authors.forename: Nagavamsikrishna
authors.initials: N
authors.lastname: Ambatipudi
authors.affiliation: Molecular Endocrinology Laboratory, Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247 667, Uttarakhand, India.
authors.forename: Partha
authors.initials: P
authors.lastname: Roy
authors.affiliation: Department of Basic Sciences-Chemistry, Madanapalle Institute of Technology and Science (MITS), Madanapalle 517 325, Chittoor District, Andhra Pradesh, India.
authors.forename: Venkata Raman
authors.initials: VR
authors.lastname: Bokka
authors.affiliation: Biomedical research Laboratory, Department of Biotechnology, K L University, Green fields, Vaddeswaram, Guntur 522 502, AndhraPradesh, India.
authors.forename: Mahendran
authors.initials: M
authors.lastname: Botlagunta
keywords: Apoptosis; DDX3; Sophora interrupta; cancer cell lines
references.citation: Biochim Biophys Acta. 2010 Aug;1806(1):29-35
references.pmid: 20193746
references.citation: Future Oncol. 2011 Feb;7(2):239-51
references.pmid: 21345143
references.citation: Toxicol In Vitro. 2010 Jun;24(4):1215-28
references.pmid: 20152895
references.citation: Curr Drug Targets. 2011 Oct;12(11):1595-653
references.pmid: 21561421
references.citation: Drug Discov Today. 2008 Oct;13(19-20):894-901
references.pmid: 18691670
references.citation: Nucleic Acids Res. 2013 Jan;41(Database issue):D1124-9
references.pmid: 23203877
references.citation: Transl Oncol. 2010 Feb;3(1):1-12
references.pmid: 20165689
references.citation: Endocr Relat Cancer. 2010 Jan 29;17(1):R39-52
references.pmid: 19926708
references.citation: Oxid Med Cell Longev. 2013;2013:925804
references.pmid: 24454991
references.citation: Mol Cancer Ther. 2008 Nov;7(11):3566-74
references.pmid: 19001439
references.citation: Expert Opin Ther Targets. 2001 Apr;5(2):177-95
references.pmid: 15992175
references.citation: Pharm Res. 2008 Sep;25(9):2097-116
references.pmid: 18626751
references.citation: J Clin Microbiol. 2005 Jul;43(7):3574-5
references.pmid: 16000511
references.citation: Oncologist. 2002;7(1):73-81
references.pmid: 11854549
references.citation: J Altern Complement Med. 2006 Mar;12(2):133-9
references.pmid: 16566672
references.citation: Exp Cell Res. 2014 Jan 15;320(2):311-28
references.pmid: 24216289
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: PLoS One. 2013 Dec 03;8(12):e81907
references.pmid: 24312601
references.citation: Phytother Res. 2007 Mar;21(3):269-77
references.pmid: 17186494
references.citation: Urol Oncol. 2013 Apr;31(3):331-42
references.pmid: 21803611
references.citation: Planta Med. 2008 Feb;74(3):245-51
references.pmid: 18283616
references.citation: BMC Complement Altern Med. 2010 Apr 30;10:15
references.pmid: 20429956
references.citation: Cancer Treat Rev. 2009 Feb;35(1):57-68
references.pmid: 19004559
references.citation: Cell. 2010 Mar 19;140(6):883-99
references.pmid: 20303878
references.citation: Cell Death Differ. 2008 Dec;15(12):1887-900
references.pmid: 18846110
references.citation: Cancer Res. 2000 Apr 1;60(7):1878-86
references.pmid: 10766175
references.citation: Nat Prod Res. 2013 Oct;27(20):1823-6
references.pmid: 23406166